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Objectives To examine the outcomes of a hepatectomy for intrahepatic cholangiocarcinoma (IHC) and to 
clarify the prognostic impact of a lymphadenectomy and the surgical margin. Large series of patients who 
were surgically treated for IHC are scarce. Thus, prognostic factors and long-term survival after resection of 
IHC remain uncertain. 
Design Prospective study of patients who were surgically treated for IHC. Clinicopathologic, operative, and 
long-term survival data were analyzed. 
Setting Prospectively collected data of all consecutive patients with pathologically confirmed IHC who had 
undergone liver resection with a curative intent at 1 of 16 tertiary referral centers were entered into a multi-
institutional registry. 
Patients All consecutive patients who underwent a hepatectomy with a curative intent for IHC (1990-2008) 
were identified from a multi-institutional registry. 
Results A total of 434 patients were included in the analysis. Most patients underwent a major or extended 
hepatectomy (70.0%) and a systematic lymphadenectomy (62.2%). The incidence of lymph node metastases 
(overall, 36.9%) increased with increased tumor size, with 24.4% of patients with a small IHC (diameter ≤3 
cm) having N1 disease. Almost one-third of patients required an additional major procedure to obtain a R0 
resection in 84.6% of the cases. In these patients, the median time of survival was 39 months, and the 5-year 
survival rate was 39.8%. Lymph node metastases (hazard ratio, 2.21; P < .001), multiple tumors (hazard 
ratio, 1.50; P = .009), and an elevated preoperative cancer antigen 19.9 level (hazard ratio, 1.62; P = .006) 
independently predicted an adverse prognosis. Conversely, survival was not influenced by the width of a 
negative resection margin (P = .61). The potential survival benefit of a lymphadenectomy was assessed with 
the therapeutic value index, which was calculated to be 5.9 points. 
Conclusions Survival rates after a hepatectomy with a curative intent for IHC at tertiary referral centers 
exceed the survival rates reported in most study series in single institutions, which strengthens the value of 
an aggressive approach to radical resection. Lymph node metastases and multiple tumors are associated with 
decreased survival rates, but they should not be considered selection criteria that prevent other patients from 
undergoing a potentially curative resection. Lymphadenectomy should be considered for all patients. 
Intrahepatic cholangiocarcinoma (IHC) is the second most common primary malignant neoplasm of the 
liver, but it remains a relatively rare disease accounting for only 4% to 14% of newly diagnosed liver 
tumors.1- 4 Recently, increasing clinical interest has been focused on IHC because of the epidemiological 
documentation of a worldwide steady increase in the incidence of IHC and in the mortality rates associated 
with IHC over the last quarter century.1- 3 In Italy, analysis of data from the Italian Association of Tumour 
Registries (AIRTUM) showed a descriptive epidemiology mirroring the global trends.3 Nevertheless, the 
rarity of the disease and the high proportion of patients diagnosed at an advanced, unresectable stage5 have 
hindered the collection of large amounts of surgical data. Most of the available data derive from small single-
institution studies reporting conflicting results in terms of overall survival.6- 20 Thus, the efficacy and 
outcomes of surgical resection of IHC are still ill-defined. In addition, the lack of effective neoadjuvant or 
adjuvant protocols has reinforced the traditional perception of a dismal prognosis. Therefore, assessment of 
the potential long-term benefits of surgical resection in a large cohort of patients is necessary to support the 
aggressive surgical approach often required to treat such tumors. Furthermore, controversies exist regarding 
optimal surgical management. Despite the data from a number of studies that have investigated the 
oncologic significance of lymphadenectomy,7,8,12,16 the evidence is still inadequate, with many Western 
surgeons not including locoregional lymphadenectomy as part of their routine approach to IHCs. Similarly, 
the issue of the appropriate surgical margin remains to be adequately addressed.8,19,21- 24 As such, the 
purpose of the present study was to examine the outcome of resection of IHC in a series of patients evaluated 
and treated at tertiary hepatobiliary centers. Specifically, using one of the largest series ever collected, we 
sought (1) to determine the expected survival rate after R0 resection; (2) to identify factors associated with 
poor outcome; and (3) to clarify the prognostic impact of technical factors, namely locoregional 
lymphadenectomy and the surgical margin width. 
METHODS 
ABSTRACT | METHODS | RESULTS | COMMENT | ARTICLE INFORMATION |REFERENCES 
Prospectively collected data from all consecutive patients with a pathologically confirmed IHC who had undergone a 
liver resection with a curative intent at 1 of 16 tertiary referral centers (March 1990–December 2008) were entered into 
a multi-institutional registry. The registry and the present study were endorsed by the Italian Chapter of the 
International Hepato-Pancreato-Biliary Association. Patients with hilar cholangiocarcinoma and those with mixed IHC–
hepatocellular carcinoma were considered ineligible for registration. Data collection and analysis were performed, 
and they conformed to the ethical standards of the Helsinki Declaration. 
The preoperative workup for all patients consisted of a routine clinical evaluation, an assessment of serum laboratory 
tests, a colonoscopy and upper gastrointestinal endoscopy, computed tomography or magnetic resonance imaging of the 
abdomen, and radiography or computed tomography of the chest. A positron emission tomographic scan and a liver 
biopsy were performed only for selected cases. Patients were deemed to have resectable disease only if the tumor could 
be completely removed while preserving a sufficient functional liver remnant with adequate vascular inflow and hepatic 
venous outflow. Distant metastases at preoperative staging were the only formal contraindication to surgery. 
After hepatic resection, adjuvant chemotherapy was decided based on recommendations from each 
institutional multidisciplinary team meeting or from the patient's oncologist. Patients were regularly 
followed up every 3 to 6 months according to each institution's protocol. Follow-up data were updated on 
January 1, 2010. 
The following clinicopathologic variables were recorded for each patient: demographics, preoperative 
carcinoembryonic antigen and cancer antigen 19-9 levels, details of the operation, whether or not there were 
postoperative complications, characteristics of tumor, and complete follow-up data including disease status 
and site of recurrence. All pathologic data were retrospectively reviewed to confirm the consistency of the 
data recorded in each prospectively collected database for the variables of interest: gross pathology 
(macroscopic typing was based on the Liver Cancer Study Group of Japan's classification25), size and number 
of tumors, histological differentiation, whether or not there was vascular invasion, lymph node (LN) status, 
whether or not there was adjacent organ invasion, and the presence of distant metastases. For each patient, 
the TNM stage grouping was computed according to the criteria of the seventh edition of theAJCC Cancer 
Staging Manual.26 Data on margin status and the underlying liver were also recorded. In particular, the 
surgical margin was classified as positive in patients with an exposed tumor along the line of transection or in 
those with microscopic evidence of tumor cells at the cut surface. Missing data were recorded as 
nonavailable. Postoperative morbidity was defined using the classification of Dindo et al.27Postoperative 
mortality was analyzed 90 days after surgery. 
Variables are presented as absolute numbers and percentages or as median values and ranges. Statistical 
analyses of data were performed with appropriate nonparametric tests. Overall survival estimates were 
generated with the Kaplan-Meier method measuring time from the date of surgery to the date of death or last 
follow-up. Cox proportional hazards models were developed to test the association of relevant 
clinicopathologic factors with survival. All factors with a univariate P < .100, with the exception of those at 
risk of multicollinearity (specifically T stage and AJCC stage factors), were considered for independent 
comparison using a multivariable model. To overcome the limitations of a multivariable analysis of a data set 
containing missing values, a second analysis was performed using regression imputation to account for 
missing data.28 Regression imputation was applied to a model that included only the variables selected with a 
stepwise procedure; all other variables of the multivariable model were used to fill in the missing data. To 
assess the potential benefit of lymphadenectomy, the therapeutic value index, calculated by multiplying the 
frequency of LN metastasis and the 5-year survival rate of patients with LN metastasis, was 
computed.29Statistical significance was set at P < .50. The R environment version 2.13.0 (The R Foundation 
for Statistical Computing, Vienna, Austria) software package was used for statistical analyses. 
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CHARACTERISTICS OF PATIENTS 
In total, 434 patients were registered. There were 243 male patients (56.0%) and 191 female patients (44.0%), with a 
median age of 65 years (range 29-85 years). Of these 434 patients, 39 (8.9%) tested positive for serum hepatitis B 
surface antigen, and 53 (12.2%) tested positive for the presence of hepatitis C antibody (7 patients had a coinfection 
with hepatitis B virus and hepatitis C virus). Preoperatively, 195 of 325 patients (60.0%; 109 patients [25.1%] were not 
tested) had an elevated (ie, >37 U/mL [to convert to kilounits per liter, multiply by 1.0]) cancer antigen 19-9 level 
(median, 57.1 U/mL; range, 0.2-27 000 U/mL). Conversely, an increased carcinoembryonic antigen level (ie, >5 ng/mL 
[to convert to micrograms per liter, multiply by 1.0]) was detected only in 77 of 288 patients (26.7%; 146 patients 
[33.6%] were not tested) (median, 2.3 ng/mL; range, 0.1-36 000 ng/mL). Sixty patients (13.8%) presented with 
obstructive jaundice, 37 of whom (61.6%) underwent preoperative biliary drainage. 
SURGICAL RESULTS 
The type and extent of surgical procedures are detailed in Table 1. During the postoperative period, 151 patients 
(34.8%) experienced a total of 182 adverse events. Complications were primarily related to the liver (43.9%), including 
hepatic dysfunction/hepatic insufficiency (16 and 22 patients, respectively) and biliary fistula (42 patients). Infectious 
complications (34 of 182 patients [18.7%]) were the second most common cause of morbidity, the most common being 
subphrenic abscess, pneumonia, and sepsis. Overall, 89 of 434 patients (20.5%) developed major (grades III-V) 
complications with a reoperation rate of 3.7% (16 patients). Of note, morbidity was significantly higher in patients who 
had undergone a biliary drainage (67.5%) (P = .058) compared with patients with jaundice who did not undergo biliary 
drainage (43.5%) and compared with patients without jaundice (31.3%) (P < .001). In all, 23 patients (5.3%) died 
postoperatively.After splitting the series into 3 groups using tertiles, the mortality rate decreased from 6.2% in 
the first two-thirds of patients to 3.5% in the last third of patients. However, such a decrease in mortality, 
which was observed in spite of a similar complexity of resections, was not statistically significant (P = .24). 
The median length of hospital stay was 12 days (range, 1-114 days) from the day of surgery. After resection, 
124 patients (30.2%) received adjuvant treatments, either chemotherapy (116 patients) or radiotherapy (8 
patients). 
Table 1. Data on Surgical Procedures Performed for Patients Who Underwent a Hepatectomy With a Curative Intent for 
Intrahepatic Cholangiocarcinoma 
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PATHOLOGIC FINDINGS 
The descriptive pathologic characteristics of the study cohort are detailed in Table 2. The overall incidence of 
LN metastases was 36.9% in patients who had undergone some form of LN dissection. As tumor size 
increased, the incidence of nodal involvement increased (≤3 cm, 24.4% of patients; 3.1-5 cm, 32.8% of 
patients; 5.1-10 cm, 38.6% of patients; and ≥10 cm, 51.6% of patients [P = .012]). Similarly, the incidence of 
multiple tumors, vascular invasion, and poorly undifferentiated tumors increased with tumor size 
(allP < .005) (Figure). 
Figure. Relation between tumor size and other pathologic parameters of 434 patients who underwent a hepatectomy with a curative intent for 
intrahepatic cholangiocarcinoma. LN indicates lymph node. 
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Table 2. Pathologic Features of the Patients Who Underwent a Hepatectomy With a Curative Intent for IHC 
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On final pathologic analysis, 52 patients (12.0%) had a positive resection margin. The median width of tumor-free 
margin was 10 mm (range, 0.5-40 mm). Stratification for margin width was 0.5 to 9 mm (median width, 4 mm) for 133 
patients (30.6%) and 1 cm or larger (median width,15 mm) for 159 patients (36.6%). Data on margin width were 
unavailable for 90 patients (20.7%), and data on margin status were unavailable for 5 patients (1.2%). Overall, 67 
patients (15.4%) were classified as having received an R1 resection. The causes of resections that were not radical (ie, 
R1 resections) were a positive resection margin (52 patients); intraoperatively discovered peritoneal implants (12 
patients), albeit completely resected; positive paracaval LNs (1 patient); and IHCs in the remnant liver (2 patients). 
These last 2 patients for whom a 2-stage hepatectomy was initially planned eventually did not undergo the second 
resection because of tumor progression. 
OVERALL SURVIVAL AND PROGNOSTIC FACTORS 
At the time of analysis, 218 of 411 patients (53.0%) had died. After a median follow-up of 36.5 months (range, 
1-181 months), overall median survival was 33 months (95% CI, 27.0-39.1 months), and the 1-, 3-, and 5-year 
estimates were 82.3%, 47.1%, and 32.9%, respectively. After R0 resection, corresponding survival estimates 
were 39 months (95% CI, 28.7-49.2 months), and the 1-, 3-, and 5-year estimates were 84.8%, 50.6% and 
39.8%, respectively. The longest living survivor was alive and disease-free at 15.1 years, with 47 actual 5-year 
survivors (26.8% of those 175 patients with at least 5 years of follow-up). Of these patients, 31 had no 
evidence of disease for a minimum cure rate of 17.7%. 
The univariate and multivariate predictors of overall survival are reported in Table 3. On univariate analysis, 
an elevated preoperative cancer antigen 19-9 level, all pathologic tumor factors with the exception of 
macroscopic typing and perineural invasion, and the radicality of resection proved to correlate with survival. 
On multivariate analysis, only LN metastases (hazard ratio, 2.21 [95% CI, 1.55-3.15]; P = .005), multiple 
tumors (hazard ratio, 1.50 [95% CI, 1.11-2.04]; P < .001), and an elevated preoperative cancer antigen 19-9 
level (hazard ratio, 1.62 [95% CI, 1.15-2.30]; P = .006) remained independent predictors of poor survival. 
Similar results were obtained in the second set of analyses using regression imputation to account for 
missing data. The corresponding hazard ratios were 2.01 (95% CI, 1.49-2.72) for LN metastases (P < .001), 
1.57 (95% CI, 1.16-2.10) for multiple tumors (P = .004), and 1.60 (95% CI, 1.16-2.21) for an elevated 
preoperative cancer antigen 19-9 level (P = .004). 
Table 3. Predictors of Overall Survival: Univariate and Multivariate Analysesa 
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IMPLICATIONS FOR SURGICAL MANAGEMENT 
First, as the presence of metastatic nodal disease emerged as the most powerful, independent determinant of 
survival, we attempted to evaluate the potential survival benefit of lymphadenectomy. The 5-year overall 
survival rate in patients having positive LNs was 15.9%. The therapeutic value index for the survival benefit 
was calculated to be 5.9 points (15.9 × 0.369). Notably, only 2 patients developed a clinically significant 
lymphorrhea. 
Second, we investigated the prognostic significance of the resection margin. In particular, we tested our a 
priori hypothesis that all hepatectomies with negative margins (>0 mm), regardless of the margin width, 
should be considered radical resections. We found that the width of a negative margin has no long-term 
impact because survival estimates in patients with a negative margin of 0.5 to 9 mm and survival estimates in 
patients with a negative margin of 1 cm or larger are similar (P = .61) and significantly better than those in 
patients with a positive margin (P < .001). In addition, although tumor recurrence was significantly more 
likely to occur in patients with a positive margin (73.6% vs 53.9%; P = .005), in patients with a negative 
margin, the margin width did not predict tumor relapse or the site of recurrence (all P > .05). 
COMMENT 
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Intrahepatic cholangiocarcinoma remains a rare neoplasm despite a steady increase in the incidence of IHC 
and in the mortality rates associated with IHC worldwide.1- 3 Although liver resection is the only curative 
treatment, the rarity of the disease has hampered significant progress in terms of surgical approach and 
outcome. In addition, because effective adjuvant protocols are still lacking, the prognosis is generally 
perceived as unsatisfactory.6- 15,17,19,22,30 By contrast, the present study, which analyzes one of the largest 
contemporary series of resected IHCs from tertiary referral centers, provides new evidence supporting the 
effectiveness of an aggressive surgical approach. First, adoption of a rigorous patient-selection process 
resulted in a formally curative (R0) resection in 84.6% of patients, a rate significantly higher than that 
reported in most series.6- 20,22,30,31 The type of surgery, which entailed major or extended hepatectomies in 
70% of patients and the association of additional major procedures in one-third of patients, might have 
contributed to this result. Interestingly, this aggressive surgical approach did not translate into a prohibitive 
perioperative risk. Rather, in the most recent years, the mortality rate has almost halved, a fact that likely 
reflects progress in surgical techniques and perioperative care. It can be hypothesized that this growing 
experience, by facilitating the selection of complex surgical procedures such as extended hepatectomies, may 
provide a chance for a cure for patients with formerly nonresectable tumors. Second, the 5-year overall 
survival rate of 39.8% exceeds the survival estimates reported in most single-center series.6- 20,22,30Although 
reports based on retrospective multi-institutional cooperations have intrinsic limitations, in the present 
study, the collection of data from multiple centers might have reduced possible patient-selection and referral 
biases. Thus, the results from the data herein presented on long-term survival, both actuarial and actual, 
should be regarded as remarkable and repeatable. 
The present study is also important because, by analyzing a cohort of more than 400 patients, it provides 
robust and generalizable results on the prognostic significance of various clinicopathologic factors. Such 
results are crucial not only for predicting a prognosis after resection but also for permitting a precise patient 
stratification in clinical research based on the individual risk of death. At present, however, despite 
promising results in terms of progression-free survival and tumor response obtained with chemotherapy for 
patients with unresectable biliary tract cancer,32,33 we believe that our findings cannot be used to routinely 
recommend neoadjuvant treatments for high-risk patients with resectable tumors. We found that the most 
important, independent determinant of survival was the presence of LN metastases and that 36.6% of 
patients who had their LNs evaluated had N1 disease, a percentage similar to that noted in previous 
reports.11- 16,18,22,30 Although some Western surgeons are still reluctant to routinely perform a locoregional 
lymphadenectomy,18,22,30 in aggregate, our findings argue in favor of including this procedure as a standard 
approach for all patients undergoing a hepatectomy for IHC. This surgical step is, in fact, essential for 
accurately staging as N1 the tumors in a significant proportion of patients who might be candidates for 
adjuvant therapies. Noteworthy is the observation that this is true also for patients with very small IHCs. We 
found that 24.4% patients with IHCs 3 cm in diameter or smaller have LN metastases, a percentage that 
progressively increases with increasing tumor size. We are aware that this incidence might be overestimated 
because roughly one-third of patients (27.9%) did not undergo a lymphadenectomy. Nevertheless, the 
prevalence of patients with N1 disease among those with IHCs 3 cm or smaller in size would have been 15% if 
all NX tumors had been considered N0 tumors. 
Beside its staging relevance, a systematic LN dissection has the theoretical potential to improve long-term 
survival. Yet, this is still unproven. In fact, a direct demonstration of higher survival rates in patients who 
had undergone a lymphadenectomy vs those who had not is impossible because, for patients who had not 
undergone LN dissection, the N status cannot be ascertained. Therefore, we used the concept of the 
therapeutic value index, which is obtained by multiplying the incidence of LN metastases by the 5-year 
survival rate of patients with N1 disease. This index, which provides an estimation of the survival benefit of 
lymphadenectomy, is based on the assumption that none of the patients who survived for 5 years after 
resection of LN metastases would have done so if the involved LNs had been left in situ. Although the index 
value determining the indication for a systematic lymphadenectomy cannot be defined, using this index, we 
can compare LN areas in terms of the therapeutic value of a node's dissection. Notably, our therapeutic value 
index (5.9) was similar to those obtained by Ueno et al29 when they were evaluating the benefit of the 
removal of mesorectal LNs in patients with low, advanced rectal cancer. In such patients, none would argue 
about the appropriateness of the total mesorectal excision. Similarly, we can infer that, for patients with IHC, 
a routine lymphadenectomy might add a potential advantage without increasing the surgical risk. In fact, we 
noted that only 2 of 313 patients who had an LN dissection developed a clinically significant lymphorrhea, 
the sole complication that can be directly correlated with this specific, single surgical step. In addition, 
removal of metastatic LNs might reduce the risk of local recurrences similar to what has been reported in 
pancreatic cancer.34 One of the limitations of our study is that we could not determine the site of LN 
metastases in patients with N1 disease and, thus, the most appropriate extent of a lymphadenectomy. 
Nevertheless, we believe that a systematic LN dissection should at least include the first echelon LNs.25 
The second major “technical” aspect that deserves consideration in order to define the standard surgical 
approach to IHC is the resection margin. In fact, the optimal margin necessary to improve survival and to 
reduce the risk for recurrence is still uncertain.8,19,21- 24 Therefore, we tested whether our definition of an 
optimal margin (>0 mm) was oncologically adequate. Our data indicate that, similar to colorectal liver 
metastases,35 the status rather than the width of the margin is prognostically relevant. Therefore, any 
margin-negative resection should be considered a radical operation. In addition, we reported that the 
survival rates of patients with a positive margin (65.1% of patients lived for 1 year after surgery, 37.7% of 
patients lived for 3 years, and 4.7% of patients lived for 5 years), albeit significantly inferior to that of patients 
who had a negative-margin resection, compare favorably with the survival time of 6 to 12 months observed 
for patients who were managed with palliative treatments.1 Our data, however, should be interpreted in the 
light of possible biases due to missing values or the absence of information on the resection technique (Kelly-
clamp crush vs ultrasonic dissection). 
In conclusion, hepatic resection remains the only chance of a cure for patients with IHC. Our results support 
an aggressive surgical approach that results in a high R0 resection rate and enhanced long-term survival. 
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